Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA

Inclusion Criteria: * Ability to provide signed informed consent and willingness to comply with protocol requirements * Persistently elevated PSA * Scheduled for magnetic resonance imaging (MRI) fusion/transrectal ultrasound (TRUS) biopsy, followed by histology * Agree to use an acceptable form of birth control for a period of 7 days after the Cu-64-TP3805 injection Exclusion Criteria: * Participating would significantly delay the scheduled standard of care therapy * Administered a radioisotope within 10 physical half-lives prior to study drug injection * Have any medical condition or other circumstances that, in the opinion of the investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study